SCHEMBL6942002

SCHEMBL6942002

COCc1cnc(Cc2ccc3c(c2)OCO3)nc1O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 3/20 0.45
CYP3A4 P08684 1/20 0.45
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
LTB4R Q15722 1/20 0.41
IGFBP3 P17936 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6943670 0.88 SMN1; SMN2 (0.42) CALM1CYP3A4HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6942607 0.86 CYP3A4 (0.45) CALM1CYP3A4HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6939898 0.85 GAA (0.49) CALM1CYP3A4ALDH1A1HPGDGAA
SCHEMBL6945952 0.85 CALM1 (0.47) CALM1CYP3A4HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6941106 0.84 SMN1; SMN2 (0.47) CYP3A4HSD17B10SMN1; SMN2ALDH1A1NPC1
SCHEMBL6942379 0.81 TSHR (0.47) CYP3A4HSD17B10SMN1; SMN2ALDH1A1NPC1
SCHEMBL6943260 0.80 MAOB (0.51) CALM1SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL6942703 0.80 CALM1 (0.49) CALM1CYP3A4HSD17B10SMN1; SMN2ALDH1A1
SCHEMBL6943649 0.79 SMN1; SMN2 (0.42) CYP3A4HSD17B10SMN1; SMN2ALDH1A1NPC1
SCHEMBL6942293 0.78 ALDH1A1 (0.51) CALM1CYP3A4HSD17B10ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268471-B1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AG (DE) 2003-10-15 EP disclosed
US-6525051-B2 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2003-02-25 US disclosed
EP-1268471-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-01-02 EP disclosed
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors SCHERING AKTIENGESELLSCHAFT (DE) 2002-01-24 US disclosed
WO-2001072744-A1 N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS SCHERING AKTIENGESELLSCHAFT (DE) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010190-A1 N-heterocyclic derivatives as NOS inhibitors NOS1, NOS3, NOS2 CALM1 1648/4885CYP3A4 46/4885HSD17B10 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.